tag:blogger.com,1999:blog-36634196.post4465237486114102680..comments2023-10-09T11:33:37.853-05:00Comments on The IN VIVO Blog: DotW: Not Dead YetChris Morrisonhttp://www.blogger.com/profile/04075266444951558159noreply@blogger.comBlogger1125tag:blogger.com,1999:blog-36634196.post-31231423397457344762009-09-11T14:20:32.276-05:002009-09-11T14:20:32.276-05:00I thought it might tickle you that the GSK-Chroma ...I thought it might tickle you that the GSK-Chroma deal that you lampooned a while ago last night won an award.<br /><br />"Best Biotech Fundraising: Chroma Therapeutics<br /><br />Winner: Chroma Therapeutics - for its $1bn deal with GSK and a £15m equity investment<br /><br />Runners-up: BioVex, Synairgen<br /> <br />Chroma Therapeutics is a privately-held biotechnology company which is developing a pipeline of drugs targeting high-prevalence cancers and inflammatory disorders. Chroma is the first company to systematically assemble intellectual property in chromatin biology and has established a strong network of academic collaborators.<br /><br />In June 2009, Chroma struck a deal with GSK to develop novel macrophage-targeted drugs, with one of the European industry's largest headline values at $1bn, and simultaneously received a Series D funding round from existing investors and GSK worth £15m. Chroma is based at Milton Park near Oxford."<br /><br />Three Cheers for Chroma!Anonymousnoreply@blogger.com